New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
07:37 EDTTHORThoratec price target raised to $39 from $37 at Canaccord
Canaccord raised its price target on Thoratec to $39 from $37 following the company's proposed acquisition of Apica. The firm sees double digit earnings potential for Thoratec given its VAD prospects and ability to target the fast growing acute MCS space and keeps its Buy rating on the stock.
News For THOR From The Last 14 Days
Check below for free stories on THOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent THOR news | >>
August 7, 2014
14:51 EDTTHORThoratec investors should not move to sidelines, says Barrington
Subscribe for More Information
14:28 EDTTHORThoratec downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
12:14 EDTTHOROn The Fly: Midday Wrap
Subscribe for More Information
10:15 EDTTHORThoratec drops sharply after results, guidance, downgrades
Subscribe for More Information
10:00 EDTTHOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:08 EDTTHOROn The Fly: Pre-market Movers
Subscribe for More Information
08:20 EDTTHORThoratec downgraded to Neutral from Buy at BTIG
Subscribe for More Information
08:08 EDTTHORThoratec price target lowered to $35 from $41 at Oppenheimer
Oppenheimer cut its price target on Thoratec after the company reported lower than expected revenue and lowered its sales guidance, but reported higher than expected EPS. However, the firm says it has seen significant lumpiness in Thoratec's market before and expects investors' focus to shift to the company's new HeartMate III product. The firm keeps an Outperform rating on the shares.
07:56 EDTTHORThoratec downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
07:42 EDTTHORThoratec price target lowered to $28 from $39 at Canaccord
Subscribe for More Information
07:31 EDTTHORThoratec long-term opportunity remains intact, says Leerink
Subscribe for More Information
06:25 EDTTHORThoratec downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
05:37 EDTTHORThoratec downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Thoratec to Neutral citing the weaker LVAD market and limited visibility following the company's Q2 results. The firm lowered its price target for shares to $28 from $38. Goldman keeps a Sell rating on peer HeartWare (HTWR) and lowered its price target on the name to $73 from $75.
August 6, 2014
18:54 EDTTHOROn The Fly: After Hours Movers
Subscribe for More Information
16:35 EDTTHORThoratec down 19.7% after reporting Q2 miss, lowers FY14 guidance
Subscribe for More Information
16:30 EDTTHORThoratec announces $30M accelerated share repurchase
Thoratec said that it has entered into a $30M Accelerated Share Repurchase, or ASR, agreement. The ASR will begin in the coming days and complete execution during Q3, and is being conducted under the $200M share repurchase authorization approved by the board in December 2013.
16:28 EDTTHORThoratec announces start of HeartMate PHP CE Mark trial
Subscribe for More Information
16:27 EDTTHORThoratec lowers FY14 EPS view to $1.25-$1.35 from $1.72-$1.82, consensus $1.75
Subscribe for More Information
16:23 EDTTHORThoratec reports Q2 EPS 43c, consensus 43c
Reports Q2 revenue $118.1M, consensus $128.27M.
16:00 EDTTHORThoratec trading halted, pending news
1 | 2 | all recent THOR news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use